

Invion Limited (ASX:IVX)

Clinical-stage life sciences company targeting chronic inflammation



Targeting inflammation

Disclaimer

- The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited ACN 094 730 417 (**Company**). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.
- Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.
- Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.
- Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.
- Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Assets in development

Respiratory

1. **INV102 (nadolol)**: beta blocker being targeted to treat chronic inflammatory airway diseases (e.g. asthma and COPD). Oral INV102 is also being studied as an aid to smoking cessation.
 - > Phase II data anticipated 3Q 2015
2. **INV104 (zafirlukast)**: leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways and the build-up of mucus in the lungs
 - > Development and manufacturing collaboration announced 3Q 2015

Autoimmune

3. **INV103 (ala-Cpn10)**: modified naturally occurring human hypothesised to maintain and restore immune homeostasis
 - > Phase II data announced 3Q 2015, partnering discussions underway




Targeting inflammation

Targeting chronic inflammatory airway disease

Oral INV102 (nadolol)


Spectrum of airway disease and opportunities



Treating the airway: background and rationale

- > Existing drugs do an excellent job in opening constricted airways: bronchodilators include β -adrenergic and anti-muscarinic drug classes
- > Existing drugs do an excellent job in decreasing inflammatory cells in the airway: inhaled corticosteroid (ICS) and anti-IL5 monoclonal antibody drug classes
- > Fixed combinations of beta agonists and ICS are the mainstay treatment of airway disease: e.g. Symbicort® and ADVAIR®
- > **However: these drugs have had NO positive impact on death due to chronic airway disease; death is due to increased abnormal mucus and inflammation**


The “vicious cycle” of chronic inflammatory airway disease



Nadolol has unique properties that could treat airway disease

- > In cell experiments, INV102 (nadolol):
 - > Blocks the β -arrestin pathway on airway epithelial cell β 2 receptors (Lefkowitz)
- > In animal experiments, nadolol:
 - > Blocks (prevents) or reduces (treats) the increase in goblet cells caused by inflammation
 - > Blocks the β -arrestin pathway in airway β 2 receptors
 - > Reduces markers of airway inflammation (IL-5) and abnormal mucus production (MUC5AC)
- > In human studies, orally administered nadolol
 - > Decreases biomarkers of inflammation (IL-8) and β -arrestin pathway activation (ERK2)
 - > Decreases airway hyper-responsiveness, a hallmark of asthma
 - > Can be safely administered by titration to minimize risk of cardiovascular side effects

Nadolol could reverse the “vicious cycle” of airway inflammation



Oral nadolol program: progress and active clinical trials and results

Clinical benefits

- ✓ the only drug targeted to address the unmet medical need of mucous metaplasia in the airway
- ✓ targeted as an add-on to existing therapies to make them safer and more effective by reducing mucous production
- ✓ targeted to assist lung healing and aid smoking cessation in patients trying to quit

Development strategy

- ✓ proof of concept
- ✓ identify speed to market commercial strategy (smoking cessation)
- ✓ identify wider use and IP opportunity (inhaled nadolol)
- ✓ phase II trials in mild asthma and smoking cessation
- > safety and biomarker data from phase II trials underpins inhaled drug program
- > endpoint in smoking cessation trial leads to EOPII / Phase III

Development program

- ✓ pharmacology is based on biased ligand and inverse agonist activity at beta receptor in airway
- ✓ chemistry and manufacturing, including titration dose development
- ✓ toxicology and metabolism profile
- ✓ IND status
- ✓ 2 x proof of concept studies in patients with mild asthma (Hanania)
- ✓ phase II in mild asthma (NIH sponsored, ongoing) & Phase II in smoking cessations (reports Q3 2015)
- ✓ interim data shows clinically relevant changes in biomarkers of inflammation
- > Final data to characterize airway epithelial response through biochemical markers; design next oral and inhaled studies; and create new intellectual property based on correlations of safety and efficacy with biochemical marker profiles.

Oral nadolol: 155 patient phase II smoking cessation study reporting Q315.

Leveraging the data: upcoming analysis and reporting

Third quarter planned analyses and reporting

Fourth Quarter

Biomarkers

- > Report on effects of nadolol vs placebo on key biomarkers
 - > IL-8 (neutrophil attraction)
 - > ERK2 (beta arrestin pathway)
 - > MUC 5AC (abnormal mucus)
- > Secondary analysis of responders and biomarker changes - identifying markers that are/are not useful in longer term studies

Smoking cessation

- > Report on smoking cessation rates in nadolol treatment versus placebo
- > Secondary analysis is on reduction versus cessation rates
- > Dose responses and responders as a function of dose, titration and history

Combined data

- > Correlation of smoking cessation/ reduction data with baseline biomarkers
- > Correlation of smoking cessation/ reduction data with biomarker changes
- > New IP prosecution

Oral nadolol: 155 patient phase II smoking cessation study reporting Q315.

Positive endpoint data

Leads to

Safety

- > Safety of titration doses
- > No need for rescue medication
- > Safely delivered to smokers trying to quit

+

Biomarkers

- > Report on effects of nadolol vs placebo on key biomarkers IL8, ERK2, MUC5AC.

+

Smoking cessation

- > Report on smoking cessation rates in nadolol treatment versus placebo

=

Oral nadolol program:
end of Phase II meeting
with FDA / Phase III

PLUS

Inhaled nadolol program:
development to proof of
concept / Phase II

Oral nadolol: 155 patient phase II smoking cessation study reporting Q315.

Positive endpoint data

Leads to

Safety

- > Safety of titration doses
- > No need for rescue medication
- > Safely delivered to smokers trying to quit

+

Biomarkers

- > Report on effects of nadolol vs placebo on key biomarkers IL8, ERK2, MUC5AC.


Smoking cessation

- > Report on smoking cessation rates in nadolol treatment versus placebo

=

Inhaled nadolol program:
development to proof of concept / Phase II in asthma, COPD and cystic fibrosis

Nadolol franchise: progressively de-risked





Targeting inflammation

Respiratory therapeutics: inhaled program

INV102 (nadolol) in asthma, COPD & cystic fibrosis

Inhaled nadolol program: progress and clinical development strategy

Clinical benefits

- ✓ once daily dosing directly to the site of injury at 1/100 of the oral dose to mitigate systemic side effects
- ✓ targeted for long term use in COPD, severe asthma and cystic fibrosis as an add-on to existing therapies to make them safer and more effective by reducing mucous production and enabling lung healing
- > Medium-term development: combination therapies
 - > inhaled nadolol + ICS (Asthma)
 - > inhaled nadolol + LAMA or LABA (COPD)
 - > inhaled nadolol + antibiotics (CF)

Status of collaboration with 3M Drug Delivery systems for proprietary formulation and device using 3M's pressurised metered dose inhalation (pMDI) technology

- ✓ Formulation and device selected
- ✓ Toxicology supplies manufactured
- ✓ Clinical supplies manufactured
- ✓ Toxicology supplies provided to CRL (Montreal QUE); toxicology studies have commenced

Development program

- ✓ Pre-IND status with FDA
- ✓ Commencement of toxicology studies
- > IND submission (2016*)
- > Phase I and Phase II clinical studies in asthma, COPD and cystic fibrosis (2016-7*)

*The information above (and where reflected elsewhere in this presentation) sets out indicative timeframes and assumes: Invion will continue to obtain the full benefit of the available R&D tax incentive for its eligible R&D activities and clinical trials; the studies will proceed based on budgeted costs, assuming normal patient recruitment and clinical trial timelines, and with no material regulatory hurdles; and ordinary R&D expenditure will continue broadly at the same levels as for past financial years

Inhaled INV102: program status



- > Collaboration with 3M Drug Delivery systems
- > Target outcome: proprietary formulation and device using 3M's proprietary pressurised metered dose inhalation (pMDI) technology
- > Collaboration encompasses manufacture for toxicology and phase I studies
- > Formulation and device selected
- > Toxicology supplies manufactured
- > Clinical supplies manufactured
- > Toxicology supplies provided to CRL (Montreal QUE); short-term toxicology ongoing

Nadolol franchise: market size, relevance and interconnectedness

Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe chronic lung diseases that cause limitations in lung airflow.

\$47.1
billion by
2017

The global market for respiratory drugs is estimated to be **\$47.1 billion by 2017**.

Nadolol is targeted to be used in conjunction with existing therapies to make them safer and more effective representing a niche in an existing large and growing market.



\$3.8
billion by
2017

The smoking cessation drug market is predicted to be **\$3.8 billion by 2016**.

Nicotine-focussed therapies comprise the bulk of the existing market, but they do not address lung healing. **Nadolol** represents an opportunity to add-on and expand an existing market.



Targeting inflammation

INV104 (zafirlukast)

Target: a novel inhaled non-steroidal anti-inflammatory treatment for asthma


Target: an inhaled reformulation of a successful oral therapeutic for asthma

INV104 (zafirlukast):

- > Leukotriene-receptor antagonist (LTRA) or “anti-leukotriene” that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs
- > Approved worldwide as an oral tablet for asthma (AstraZeneca)
- > Well established clinical efficacy & safety profile
- > Inhaled proof of concept using propellants that are now banned (CFCs)
- > Inhaled formulation indicated as monotherapy for mild persistent asthma and exercise-induced asthma
- > Indicated to reduce inhaled corticosteroid (ICS) dependency in adults and children
 - > as an alternative as first controller medication in mild persistent and moderate asthma
 - > by addition of low dose ICS treatment rather than doubling ICS
 - > by enabling reduced ICS dose “steroid sparing” in steroid-dependent asthma



Inhaled zafirlukast an anti-leukotriene: background and rationale



- > Zeneca (now A/Z) stopped inhaled development in mid 1990s.
- > Zafirlukast and montelukast have resisted formulation in non-cfc propellant systems.

FDA pre-IND established framework for reformulation of zafirlukast

Agreement reached with FDA on:

- > chemistry manufacturing and controls (GMP)
 - > active pharmaceutical ingredient (API) with drug master file (DMF)
 - > formulation: dry powder inhaler (DPI) approved for development
- > toxicology and bioanalytical assay (GLP) to support 4 weeks' dosing
 - > 2 species for 28 days: naso-pulmonary exposure
 - > 1 species for 6 months
- > IND submission and clinical program
 - > phase I: single rising dose study for safety (paradoxical bronchoconstriction) and pharmacokinetics
 - > phase I: multiple dose safety study for safety (paradoxical bronchoconstriction) and pharmacokinetics
 - > phase II: challenges to reprise previous studies: cold air, exercise and allergen [cat and ragweed]; steady state dosing for signs and symptoms of asthma [diary card] and attenuation of response to exercise and/or allergen

Inhaled Product Rationale

	Oral Forms	Inhaled Form
Risk of neuropsychiatric/suicide ideation events?	✓	
Risk of liver toxicity ?	✓	
Greater efficacy due to higher airway concentrations		✓
Potential for once a day dosing ?		✓
Potential for expanded EIB claims ?	Singulair Prevention Only	✓
Rapid onset-of-action for prophylaxis ?		✓
Potential claim to reduce use of Steroids/ LABA ?		✓
Potential claim for use in children >5 years ?		✓
Combination with ICS for anti-inflammatory effect?		✓

Hovione CMC collaboration mitigates major risk of inhaled zafirlukast development

Formulation & device partner, Hovione

- > Invion will collaborate with Hovione to develop the proprietary novel technology – a dry powder formulation of zafirlukast and the accompanying inhalational delivery device
- > under the terms of the agreement, Hovione will provide chemistry and manufacturing services to develop and optimise the dry powder inhalation formulation which will be delivered using its proprietary device technology known as the XCaps inhaler system
- > Hovione device is ideally suited for fixed combination with ICS, bronchodilators, or INV102 (nadolol).
- > IP protection provided under licence via Hovione formulation and device, Invion retains commercialisation rights

CMC solution complements existing and planned toxicology and clinical packages

- > previously completed using CFC-based device
- > Clinical proof of concept based on inhalational challenge studies; previously completed using CFC-based device

About Hovione and the XCaps inhaler

- > International company with over 50 years' experience in the development and compliant manufacture of active pharmaceutical ingredients and drug product intermediates
- > With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets
- > In the inhalation area, Hovione is the only independent company offering such a broad range of services.




XCaps is a patent protected device filed and granted in over 40 countries, including US (US 8677992) and EU (EP 2546460). XCaps device is simple, reusable and low-cost. This DPI is indicated for applications where a chronic or a medium term acute capsule based delivery of an API is needed.

Expected placement of inhaled zafirlukast in treatment regimes

- > As many as 334 million people have asthma which occurs in people of all ages. Wheeze is the most common symptom and the burden of disability is high.
- > In 2007 the U.S. spent over \$56 billion on asthma care, of which nearly \$27 billion was spent on pediatric asthma.

Inhaled zafirlukast

- > targeted for use as a controller/preventer with few or no side effects for the full range of asthma therapy
- > especially useful in LTD4-driven asthma including aspirin sensitivity and in children
- > indicated as steroid sparing
- > inhaler will facilitate substitution for inhaled corticosteroids (ICS)
- > for many patients, inhaled product alone (monotherapy) will be effective



Inhaled zafirlukast program: progress and clinical development strategy

Clinical benefits

- ✓ FDA approved as an oral asthma therapy
- ✓ Proof of concept previously conducted using inhaled drug
- ✓ Non-steroidal
- ✓ Higher local concentrations without systemic exposure (decreased risk of generic duplication)

Status of collaboration with Hovione for proprietary formulation and device using Hovione's patented XCaps inhaler system

- ✓ Formulation and device selected
- ✓ Program of works for manufacture of toxicology and clinical supplies
 - > Formulation complete for toxicology (non GMP) (3Q2015)
 - > Manufacture of toxicology supplies (4Q2015-1Q2016*)
 - > Clinical materials manufactured to support IND and Phase 1 (2Q-3Q 2016*)

Development program

- ✓ Pre-IND status with FDA
- ✓ Formulation and device collaboration
 - > Commencement of toxicology studies (4Q2015*)
 - > IND submission (3Q2016*)
 - > Phase I and Phase II clinical studies in (3Q2016 – 2Q2017*)

*The information above (and where reflected elsewhere in this presentation) sets out indicative timeframes and assumes: Invion will continue to obtain the full benefit of the available R&D tax incentive for its eligible R&D activities and clinical trials; the studies will proceed based on budgeted costs, assuming normal patient recruitment and clinical trial timelines, and with no material regulatory hurdles; and ordinary R&D expenditure will continue broadly at the same levels as for past financial years



Targeting inflammation

Targeting chronic inflammation caused by
autoimmune disease

INV103 (ala-Cpn10)

INV103 (ala-Cpn10): background and rationale

- > Minimally modified form of naturally occurring protein
- > Maintains heptameric structure and function
- > Intracellular function: prevent protein misfolding
- > Extracellular function: Cpn10 proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family (Shields et al, Clin Exp Immunol, 2011, 165: 292-300) a critical component of prevention of autoimmunity
- > Significant clinical data base > 250 patients
 - > demonstrated anti-inflammatory and immunoregulatory activity in multiple indications including RA, psoriasis
- > Strong pre-clinical data in lupus animal model (3 studies)
 - > reduced renal and circulating levels of key pro-inflammatory mediators (TNF- α , IL-6 and MCP-1)
 - > reduced CD4+ T cells and auto-reactive T cells and increased the number of activated DC (critical in the establishment of self tolerance)
- > Toxicology support through 3 months' dosing
- > Intellectual Property position: composition of matter protection in all major markets (US 2026)

INV103 (ala-Cpn10): phase II lupus data

- > Three sets of data were reviewed from subjects who received twice-weekly doses of 10, 30 or 100mg of ala-Cpn10, or placebo
- > INV103 (ala-Cpn10) well tolerated at 3 and 10 times previous highest dose
- > 10mg iv twice weekly showed no effect on stimulated peripheral blood mononuclear cells (PBMC) production of 3 key cytokines (IL-1Beta, IL-6 and TNF-alpha) at 1 month of dosing
- > In contrast, 30mg and 100mg iv twice weekly showed reduced response to stimulation by LPS after 1 month of dosing
- > These data reflect relevant activity at the target cell type in patients with a target (autoimmune) disease
- > Extending these findings will require a partner. Data is now being provided to pharma groups with a view to partnering the program

Pipeline

	Research	Formulation development and clinical feasibility	Phase I	Phase II	Next milestone
Oral INV102 (nadolol)					
Asthma	NIH funded				Completion of enrolment 2H15, Reporting 2016
Smoking cessation					Phase II data 3Q15
Inhaled INV102 (nadolol)					
Asthma					Pre-IND status achieved 1Q15 Tox and clinical supplies manufacture underway Tox studies commenced 1H15
COPD					
Cystic Fibrosis					
Inhaled INV104 (zafirlukast)					
Asthma	partnered with Hovione				Manufacture of tox supplies 4Q15
INV103 (ala-Cpn10)					
Lupus (SLE)					Partnering

Program targets: 12-18 months

Oral INV102 (nadolol)

- > advanced into Phase III as an adjunct to smoking cessation in patients with chronic cough and/or chronic bronchitis
- > IP based on combination of nadolol safety and efficacy with diagnostics from smoking cessation study

Inhaled INV102 (nadolol)

- > proprietary formulation in PMDI (CMC)
- > completion of toxicology program in 2 species to support POC (Tox)
- > completion of robust Phase I program to support phase II in 3 indications

Inhaled INV104 (zafirlukast)

- > proprietary formulation and device
- > completion of toxicology 28 days, 2 species with Charles River Labs
- > phase I studies showing safety of inhaled zafirlukast
- > plans for repeat of Phase II studies which had previously provided POC (1994)

*The information above (and where reflected elsewhere in this presentation) sets out indicative timeframes and assumes: Invion will continue to obtain the full benefit of the available R&D tax incentive for its eligible R&D activities and clinical trials; the studies will proceed based on budgeted costs, assuming normal patient recruitment and clinical trial timelines, and with no material regulatory hurdles; and ordinary R&D expenditure will continue broadly at the same levels as for past financial years

Board and Management with proven track record

- > **Chairman of Board of Directors, Mr Brett Heading**
 - > Senior partner of law firm McCullough Robertson, 27 years as a company director. Former Chairman, ChemGenex Pharmaceuticals (sold to Cephalon \$230M); former Director, Peplin Biotech Limited.
- > **Managing Director & CEO, Dr Greg Collier**
 - > 20 year career in pharmaceutical research, development and commercialisation, former CEO ChemGenex Pharmaceuticals, 150 peer reviewed publications, 33 patents, Roche Award for Excellence
- > **Executive VP R&D and CMO, Dr Mitchell Glass**
 - > 25 year veteran of the pharmaceutical industry, Graduated from the University of Chicago, board certified in internal medicine, pulmonary and critical care medicine. Senior executive roles at AZ & GSK. 5 FDA-approved drugs, including “first in class” and for the beta blocker carvedilol (Coreg®).
- > **James Campbell, PhD MBA, Non- executive Director**
 - > Senior biotechnology director and executive with 20+ years experience in research, research management, advisory. Formerly COO and CFO, ChemGenex Pharmaceuticals.
- > **Warren Brown, B Eng, Non-executive Director**
 - > Experienced in corporate strategy and project management. Background in consulting engineering and contract negotiation.

Corporate snapshot

Sector	Life Sciences (Biotechnology)
Principal activities	Clinical-stage pharmaceutical drug development
Pipeline	3 drug assets, multiple clinical and pre-clinical programs
Operations	Australia & USA
ASX code	IVX
Share price (4-Sep-15)	\$0.014
Shares on issue	~894 M
Options on issue	~115M
Market cap (4-Sep-15)	\$12.5M
Cash at bank (30-Jun-15)	\$2.285M
Placement completed with US institutional investor (1-Sep-15)	\$1M



Targeting inflammation

Dr Greg Collier
Managing Director and CEO
Invion Limited

c/- McCullough Robertson Lawyers,
Level 11, 66 Eagle Street Brisbane, QLD, 4000
Australia

P: +61 7 3295 0500

E: greg.collier@inviongroup.com

W: www.inviongroup.com

Investor Presentation
September | 2015